Abstract
The metabolic syndrome (MetS) is a cluster of metabolic conditions associated to abdominal obesity, such as elevated blood pressure, impaired glucose tolerance, insulin resistance, elevated triglycerides, and low high-density lipoprotein cholesterol concentrations. Each of the associated conditions has an independent effect, but clustering together they become synergistic, making the risk of developing cardiovascular disease (CVD) greater. There is a big debate as to whether the MetS alone or its associated health conditions are more important for CVD incidence and mortality or whether prevention and/or treatment of the MetS will reduce CVD incidence and mortality. This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues.
Keywords: Metabolic syndrome, cardiovascular disease, coronary heart disease, diabetes mellitus, lipids, blood pressure.
Current Vascular Pharmacology
Title:Metabolic Syndrome and Cardiometabolic Risk Factors
Volume: 11 Issue: 6
Author(s): Emilia Papakonstantinou, Vaia Lambadiari, George Dimitriadis and Antonis Zampelas
Affiliation:
Keywords: Metabolic syndrome, cardiovascular disease, coronary heart disease, diabetes mellitus, lipids, blood pressure.
Abstract: The metabolic syndrome (MetS) is a cluster of metabolic conditions associated to abdominal obesity, such as elevated blood pressure, impaired glucose tolerance, insulin resistance, elevated triglycerides, and low high-density lipoprotein cholesterol concentrations. Each of the associated conditions has an independent effect, but clustering together they become synergistic, making the risk of developing cardiovascular disease (CVD) greater. There is a big debate as to whether the MetS alone or its associated health conditions are more important for CVD incidence and mortality or whether prevention and/or treatment of the MetS will reduce CVD incidence and mortality. This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues.
Export Options
About this article
Cite this article as:
Papakonstantinou Emilia, Lambadiari Vaia, Dimitriadis George and Zampelas Antonis, Metabolic Syndrome and Cardiometabolic Risk Factors, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113116660176
DOI https://dx.doi.org/10.2174/15701611113116660176 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Various Bulk Sweeteners on the Survivability of <i>Lactobacillus casei</i> 431 in Milk Chocolate: Rheological and Sensory Properties Analysis
Current Pharmaceutical Biotechnology Review of Cell and Organ Printing Patents
Recent Patents on Biomedical Engineering (Discontinued) An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews Management of Ovarian Cancer in Elderly
Reviews on Recent Clinical Trials Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure
Current Topics in Medicinal Chemistry The State of the Art in Anti-Malarial Drug Discovery and Development
Current Topics in Medicinal Chemistry Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Open Questions about Pulmonary Hypertension and Exercise Training: A Critical Review
Current Respiratory Medicine Reviews Context-Dependency of Relations Between Cardiovascular Phenotypes and Genes Involved in Sodium Homeostasis: Findings from the European Project on Genes in Hypertension
Current Hypertension Reviews Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry Mitochondrial Dysfunction, Oxidative Stress and Diabetic Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets A Review of the English and Russian Language Literature on the Osteoarticular Manifestations of Brucellosis Infection
Current Rheumatology Reviews [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Medicinal Chemistry Walnut Extract Inhibits the Fibrillization of Amyloid Beta-Protein, and also Defibrillizes its Preformed Fibrils
Current Alzheimer Research The Impact of Dietary Habits and Nutritional Deficiencies in Urban African Patients Living with Heart Failure in Soweto, South Africa – A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)